Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

Justin Ferdinandus; John Violet; Shahneen Sandhu; Rodney J. Hicks; Aravind S. Ravi Kumar; Amir Iravani; Grace Kong; Tim Akhurst; Sue Ping Thang; Declan G. Murphy; Scott Williams; Michael S. Hofman

doi:10.1007/s00259-020-04723-z

Related publications

Article2023

LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).

Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Megan Crumbaker, Mathias Bressel, Rhonda Huynh, Patricia Banks, Roslyn Wallace, Anis Hamid, Andrisha Jade Inderjeeth, Ben Tran, Arun Azad, Ramin Alipour, Grace Kong, Aravind Ravi Kumar, Javad Saghebi, Scott Williams, Timothy Akhurst, Rodney J. Hicks, Michael S. Hofman

Article2021

177Lu-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)

Michael S. Hofman, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M. Joshua, David A. Pattison, Jeffrey C. Goh, Ian Kirkwood, Thean Hsiang Tan, Roslyn J. Francis, Siobhan Ng, Natalie Rutherford, Craig Gedye, Andrew M. Scott, Sze-Ting Lee, Andrew Weickhardt, Shakher Ramdave, Edmond M. Kwan, Arun Azad, W A Macdonald, Andrew D. Redfern, Alison Y. Zhang, ,

Article2018

[Lu-177]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer reply

Michael S. Hofman, John Violet, Rodney J. Hicks, Shahneen Sandhu

Article2021

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski,

Letter2018

[ 177 Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer – Author's reply